pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
Taiho Pharma Canada
Taiho Pharma Netherlands B.V.
Taiho Pharma Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Sol
2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA HQ
2017 Founded
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
- Founded
- 2017
- Employees
- 13
- Programs
- 16
- Drugs
- 30
- Patents
- 0
TAS-120-203
Phase 2 · small molecule · Advanced or Metastatic Urothelial Carcinoma
TAS-120-203 for Advanced or Metastatic Urothelial Carcinoma is a Phase 2 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code TAS-120-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Taiho Pharma Netherlands B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Advanced or Metastatic Urothelial Carcinoma
- Status
- active
- Trials
- 1